Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

被引：0
|
作者：
Paul Emery
Marjolijn Van Keep
Steve Beard
Chris Graham
LaStella Miles
Steffen Marc Jugl
Praveen Gunda
Anna Halliday
Helena Marzo-Ortega
机构：
[1] University of Leeds,Leeds Institute of Rheumatic and Musculoskeletal Medicine
[2] NIHR Leeds Biomedical Research Centre,undefined
[3] Leeds Teaching Hospitals NHS Trust,undefined
[4] BresMed Netherlands BV,undefined
[5] BresMed,undefined
[6] RTI Health Solutions,undefined
[7] Novartis Pharma AG,undefined
[8] Novartis Healthcare Private Limited,undefined
[9] Novartis Pharmaceuticals UK Ltd,undefined
来源：
PharmacoEconomics | 2018年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1015 / 1027
页数：12
相关论文
共 50 条
  • [1] Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
    Emery, Paul
    Van Keep, Marjolijn
    Beard, Steve
    Graham, Chris
    Miles, LaStella
    Jugl, Steffen Marc
    Gunda, Praveen
    Halliday, Anna
    Marzo-Ortega, Helena
    PHARMACOECONOMICS, 2018, 36 (08) : 1015 - 1027
  • [2] COST-EFFECTIVENESS OF SECUKINUMAB FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN THE UK
    Emery, P.
    van Keep, M.
    Beard, S. M.
    Graham, C. N.
    Miles, L.
    Jugl, S. M.
    Gunda, P.
    Halliday, A.
    Marzo-Ortega, H.
    VALUE IN HEALTH, 2017, 20 (09) : A534 - A534
  • [3] COST-EFFECTIVENESS OF SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS IN BRAZIL
    Libanore, A.
    Huerta, C.
    Tozato, C.
    VALUE IN HEALTH, 2020, 23 : S221 - S221
  • [4] Safety of secukinumab for the treatment of active ankylosing spondylitis
    Loricera, Javier
    Galindez-Aguirregoikoa, Eva
    Blanco, Ricardo
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 627 - 634
  • [5] Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
    Buchanan, Vanessa
    Sullivan, Will
    Graham, Chris
    Miles, LaStella
    Jugl, Steffen Marc
    Gunda, Praveen
    Halliday, Anna
    Kirkham, Bruce
    PHARMACOECONOMICS, 2018, 36 (07) : 867 - 878
  • [6] Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
    Gourzoulidis, George
    Solakidi, Argyro
    Psarra, Marina
    Nikitopoulou, Eleni
    Tzanetakos, Charalampos
    CLINICAL DRUG INVESTIGATION, 2024, 44 (01) : 59 - 69
  • [7] Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
    George Gourzoulidis
    Argyro Solakidi
    Marina Psarra
    Eleni Nikitopoulou
    Charalampos Tzanetakos
    Clinical Drug Investigation, 2024, 44 : 59 - 69
  • [8] Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
    Vanessa Buchanan
    Will Sullivan
    Chris Graham
    LaStella Miles
    Steffen Marc Jugl
    Praveen Gunda
    Anna Halliday
    Bruce Kirkham
    PharmacoEconomics, 2018, 36 : 867 - 878
  • [9] Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
    Purmonen, Timo
    Puolakka, Kari
    Mishra, Dinesh
    Gunda, Praveen
    Martikainen, Janne
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 159 - 168
  • [10] THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS TUMOUR NECROSIS FACTOR a INHIBITOR BIOSIMILARS FOR ANKYLOSING SPONDYLITIS IN THE UK
    Marzo-Ortega, Helena
    Halliday, Anna
    Jugl, Steffen
    Mokashi, Soniya
    Gunda, Praveen
    Graham, Chris
    Miles, LaStella
    Beard, Steve
    van Keep, Marjolijn
    RHEUMATOLOGY, 2017, 56 : 92 - 92
12345